Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Disease Area

Disease Area Cancer

The Relentless Cancer Researcher

| Jonathan James

Sitting Down With… Ingun Holen, Professor of Bone Oncology at the University of Sheffield Medical School, Sheffield, UK.

Disease Area Pain & critical care

Putting Your Back into It

| Jonathan James

Progress in tissue engineering may offer hope to patients suffering from debilitating intervertebral disc degeneration.

Disease Area Neurological

A Neural Precedent

| Jonathan James

Interneuron activity suggests that there’s more to the story of seizure onset

Disease Area Neuroscience

Brain Network Manipulation

| Jonathan James

Cutting-edge imaging, predictive modeling and gene therapy combine for a new direction in neurodegenerative disease research

Disease Area Infectious diseases

Andes Antibody Advancement

| Jonathan James

A antibody discovery platform emerges to tackle the growing problem of Andes Hantavirus cardiopulmonary syndrome (AHCPS)

Disease Area Cancer

More than METs the Eye

| Jonathan James

The role of different types of MET mutation in lung cancer could demand a rethink of treatments.

Disease Area Immunology

Just One Shot

| Stephanie Sutton

A vaccine using mRNA demonstrates potential for broad influenza protection.

Disease Area Analytical science

Real-Time Tumor Analysis

| William Aryitey

MALDI and a SpiderMass device could save valuable surgery time

Disease Area Diagnostics & prognostics

Markers for Prognostic Progress

| Ana Robles

Better lung cancer treatment through biomarkers

Disease Area Drug discovery

Go Forth and Find a Flu Vaccine

| Kjetil Ree

Bill Gates has issued a challenge to help researchers push for a universal flu vaccine.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register